 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
19 September 2000 | Volume 133 Issue 6 | Pages 455-463
In recent years, several authors have argued that placebo-controlled trials are invariably unethical when known effective therapy is available for the condition being studied, regardless of the condition or the consequences of deferring treatment. Some have also disputed the value of placebo-controlled trials in such a setting, asserting that the comparison of new treatment with old treatment is sufficient to establish efficacy and is all that should be of interest. This article considers the ethical concerns about use of placebo controls and describes the limited ability of active-control equivalence (also known as noninferiority) trials to establish efficacy of new therapies in many medical contexts. The authors conclude that placebo-controlled trials are not uniformly unethical when known effective therapies are available; rather, their acceptability is determined by whether the patient will be harmed by deferral of therapy. If patients are not harmed, such trials can ethically be carried out. Furthermore, active-control trials, although valuable, informative, and appropriate in many circumstances, often cannot provide reliable evidence of the effectiveness of a new therapy.
Author and Article Information
From the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland.
Disclaimer: The views expressed in these papers are those of the authors. They are similar to the conclusions and principles published in a Food and Drug Administration draft guidance document (33) based on a guideline developed by the International Conference on Harmonization, a body representing regulators and industry from the United States, the European Union, and Japan. The inferential problems associated with use of equivalence designs to show effectiveness are reflected in regulations (15) and guidelines (41).
Requests for Single Reprints: Robert Temple, MD, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 5600 Fishers Lane, HFD-101/WOC II—6014, Rockville, MD 20857.
Current Author Addresses: Dr. Temple: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 5600 Fishers Lane, HFD-101/WOC II—6014, Rockville, MD 20857.
Dr. Ellenberg: Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852. MEDICINE AND PUBLIC ISSUES
Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  S. D. Halpern, R. Doyle, and S. M. Kawut The Ethics of Randomized Clinical Trials in Pulmonary Arterial Hypertension Proceedings of the ATS, July 15, 2008; 5(5): 631 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Vitiello Improving Decision Making in the Treatment of ADHD Am J Psychiatry, June 1, 2008; 165(6): 666 - 667. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Badgett Adjunctive diclofenac and spinal manipulation did not speed recovery of acute low back pain Evid. Based Med., June 1, 2008; 13(3): 75 - 75. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shinohara, K. Nishimaru, T. Sawada, A. Terashi, S. Handa, S. Hirai, K. Hayashi, H. Tohgi, Y. Fukuuchi, S. Uchiyama, et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A Randomized, Double-Blind, Aspirin-Controlled Trial Stroke, June 1, 2008; 39(6): 1827 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. de Jonge, C. L. Bockting, J. W. Schoones, P. T. Ninan, R. M. Poole, G. L. Stiles, E. H. Turner, and R. A. Tell Selective Publication of Antidepressant Trials N. Engl. J. Med., May 15, 2008; 358(20): 2180 - 2182. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Malozowski Comparative Efficacy: What We Know, What We Need to Know, and How We Can Get There Ann Intern Med, May 6, 2008; 148(9): 702 - 703. [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Daugherty, M. J. Ratain, E. J. Emanuel, A. T. Farrell, and R. L. Schilsky Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials J. Clin. Oncol., March 10, 2008; 26(8): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Kim, J.-L. Lee, M. S. Hyun, Y. R. Do, H. S. Song, J. G. Kim, S. H. Bae, H. M. Ryoo, K. U. Park, and K. H. Lee Palliative Chemotherapy Preferences and Factors that Influence Patient Choice in Incurable Advanced Cancer Jpn. J. Clin. Oncol., January 31, 2008; (2008) hym147v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Turner, A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy N. Engl. J. Med., January 17, 2008; 358(3): 252 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Freidlin, E. L. Korn, S. L. George, and R. Gray Randomized Clinical Trial Design for Assessing Noninferiority When Superiority Is Expected J. Clin. Oncol., November 1, 2007; 25(31): 5019 - 5023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Fueglistaler, M. Adamina, and U. Guller Non-Inferiority Trials in Surgical Oncology Ann. Surg. Oncol., May 1, 2007; 14(5): 1532 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Ellenberg and W. Sun Adjuvant Therapy for Gastric Cancer: How Negative Results Can Help Patients J Natl Cancer Inst, April 18, 2007; 99(8): 580 - 582. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Greenspan, H. G. Bone, M. P. Ettinger, D. A. Hanley, R. Lindsay, J. R. Zanchetta, C. M. Blosch, A. L. Mathisen, S. A. Morris, T. B. Marriott, et al. Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Randomized Trial Ann Intern Med, March 6, 2007; 146(5): 326 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Temple and N. L. Stockbridge BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective Ann Intern Med, January 2, 2007; 146(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaul and G. A. Diamond Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials Ann Intern Med, July 4, 2006; 145(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. G Miller and D. Wendler The Relevance of Empirical Research in Bioethics Schizophr Bull, January 1, 2006; 32(1): 37 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Nagasako and D. A. Kalauokalani Ethical aspects of placebo groups in pain trials: Lessons from psychiatry Neurology, December 29, 2005; 65(12_suppl_4): S59 - S65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kaul, G. A. Diamond, and W. S. Weintraub Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1986 - 1995. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kemmler, M. Hummer, C. Widschwendter, and W. W. Fleischhacker Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs: A Meta-analysis Arch Gen Psychiatry, December 1, 2005; 62(12): 1305 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Woods, R. V. Gueorguieva, C. B. Baker, and R. W. Makuch Control Group Bias in Randomized Atypical Antipsychotic Medication Trials for Schizophrenia Arch Gen Psychiatry, September 1, 2005; 62(9): 961 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Korn, S. Hunsberger, B. Freidlin, M. A. Smith, and J. S. Abrams Preliminary Data Release for Randomized Clinical Trials of Noninferiority: A New Proposal J. Clin. Oncol., August 20, 2005; 23(24): 5831 - 5836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. P. Jhirwal, P. Kulhara, D. Basu, J. Alexander, and P. Tharyan Limitations of rapid tranquillisation trial * Authors' reply The British Journal of Psychiatry, August 1, 2005; 187(2): 193 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Mann, A. J. London, and J. Mann Equipoise in the Enhanced Supression of the Platelet IIb/IIIa Receptor with Integrilin Trial (ESPRIT): a critical appraisal Clinical Trials, June 1, 2005; 2(3): 233 - 243. [Abstract] [PDF]
|
|
|
|
 |
|
 M. H. Cohen, J. R. Johnson, Y.-C. Wang, R. Sridhara, and R. Pazdur FDA Drug Approval Summary: Pemetrexed for Injection (Alimta(R)) for the Treatment of Non-Small Cell Lung Cancer Oncologist, June 1, 2005; 10(6): 363 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Snyder, C. Leffler, and for the Ethics and Human Rights Committee, America Ethics Manual: Fifth Edition Ann Intern Med, April 5, 2005; 142(7): 560 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Roden and R. Temple The US Food and Drug Administration Cardiorenal Advisory Panel and the Drug Approval Process Circulation, April 5, 2005; 111(13): 1697 - 1702. [Full Text] [PDF]
|
|
|
|
 |
|
 A Miller Ethical Issues in MS Clinical Trials Multiple Sclerosis, February 1, 2005; 11(1): 97 - 98. [PDF]
|
|
|
|
 |
|
 J. J. Swigris, W. G. Kuschner, J. L. Kelsey, and M. K. Gould Idiopathic Pulmonary Fibrosis: Challenges and Opportunities for the Clinician and Investigator Chest, January 1, 2005; 127(1): 275 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Borer Development of cardiovascular drugs: The U.S. regulatory milieu from the perspective of a participating nonregulator J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2285 - 2292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Gallant, S. Staszewski, A. L. Pozniak, E. DeJesus, J. M. A. H. Suleiman, B. Lu, J. J. Toole, and A. K. Cheng Tenofovir, Equivalence, and Noninferiority--Reply JAMA, October 27, 2004; 292(16): 1951 - 1952. [Full Text] [PDF]
|
|
|
|
 |
|
 R.B. D'Agostino Sr. and J.M. Massaro New Developments in Medical Clinical Trials J. Dent. Res., July 1, 2004; 83(suppl_1): C18 - C24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.C. Blackwelder Current Issues in Clinical Equivalence Trials J. Dent. Res., July 1, 2004; 83(suppl_1): C113 - C115. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.M. Kawut and H.I. Palevsky New answers raise new questions in pulmonary arterial hypertension Eur. Respir. J., June 1, 2004; 23(6): 799 - 801. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Kent, A. M. Fendrick, and K. M. Langa New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions Med Decis Making, June 1, 2004; 24(3): 281 - 286. [Abstract] [PDF]
|
|
|
|
 |
|
 V. Strand, S. Cohen, B. Crawford, J. S. Smolen, and D. L. Scott Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis Rheumatology, May 1, 2004; 43(5): 640 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R K Lie, E Emanuel, C Grady, and D Wendler The standard of care debate: the Declaration of Helsinki versus the international consensus opinion J. Med. Ethics, April 1, 2004; 30(2): 190 - 193. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. G. Miller and H. J. Silverman The Ethical Relevance of the Standard of Care in the Design of Clinical Trials Am. J. Respir. Crit. Care Med., March 1, 2004; 169(5): 562 - 564. [Full Text] [PDF]
|
|
|
|
|
|
F. G. Miller, E. J. Emanuel, D. L. Rosenstein, and S. E. Straus Ethical Issues Concerning Research in Complementary and Alternative Medicine JAMA, February 4, 2004; 291(5): 599 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pasquina, M. R Tramer, and B. Walder Prophylactic respiratory physiotherapy after cardiac surgery: systematic review BMJ, December 13, 2003; 327(7428): 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Leon and D. A. Solomon Toward Rapproachment in the Placebo Control Debate: A Calculated Compromise of Power Eval Health Prof, December 1, 2003; 26(4): 404 - 414. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Stolk, M. J ten Berg, M. E. Hemels, and T. R Einarson Meta-Analysis of Placebo Rates in Major Depressive Disorder Trials Ann. Pharmacother., December 1, 2003; 37(12): 1891 - 1899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Purucker, C. J. Rosebraugh, F. Zhou, and R. J. Meyer Inhaled Fluticasone Propionate by Diskus in the Treatment of Asthma: A Comparison of the Efficacy of the Same Nominal Dose Given Either Once or Twice a Day Chest, October 1, 2003; 124(4): 1584 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Olutoye, E. C. Jantzen, R. Alexis, D. Rajchert, M. S. Schreiner, and M. F. Watcha A Comparison of the Costs and Efficacy of Ondansetron and Dolasetron in the Prophylaxis of Postoperative Vomiting in Pediatric Patients Undergoing Ambulatory Surgery Anesth. Analg., August 1, 2003; 97(2): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aggarwal, S. G. Coca, G. K. Buller, D. A. Blaustein, M. H. Schwenk, B. Pitt, and the EPHESUS Investigators Eplerenone in Patients with Left Ventricular Dysfunction N. Engl. J. Med., July 3, 2003; 349(1): 88 - 89. [Full Text] [PDF]
|
|
|
|
|
|
S. Y.H. Kim and R. G. Holloway Burdens and Benefits of Placebos in Antidepressant Clinical Trials: A Decision and Cost-Effectiveness Analysis Am J Psychiatry, July 1, 2003; 160(7): 1272 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Garattini, V. Bertele, and L. L. Bassi How can research ethics committees protect patients better? BMJ, May 29, 2003; 326(7400): 1199 - 1201. [Full Text] [PDF]
|
|
|
|
|
|
W. W. Fleischhacker, P. Czobor, M. Hummer, G. Kemmler, R. Kohnen, and J. Volavka Placebo or Active Control Trials of Antipsychotic Drugs? Arch Gen Psychiatry, May 1, 2003; 60(5): 458 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Yueh and J. F. Piccirillo On Equivalence Trials and Alternative Medicine Arch Otolaryngol Head Neck Surg, April 1, 2003; 129(4): 403 - 404. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Lincoff, J. A. Bittl, R. A. Harrington, F. Feit, N. S. Kleiman, J. D. Jackman, I. J. Sarembock, D. J. Cohen, D. Spriggs, R. Ebrahimi, et al. Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention: REPLACE-2 Randomized Trial JAMA, February 19, 2003; 289(7): 853 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Temple and R. Meyer Continued Need for Placebo in Many Cases, Even When There Is Effective Therapy Arch Intern Med, February 10, 2003; 163(3): 371 - 371. [Full Text] [PDF]
|
|
|
|
|
|
W. T. Carpenter Jr., P. S. Appelbaum, and R. J. Levine The Declaration of Helsinki and Clinical Trials: A Focus on Placebo-Controlled Trials in Schizophrenia Am J Psychiatry, February 1, 2003; 160(2): 356 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.G. Gilliam, F. Veloso, M.A.M. Bomhof, S.K. Gazda, V. Biton, J.P. Ter Bruggen, W. Neto, C. Bailey, G. Pledger, and S.-C. Wu A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy Neurology, January 28, 2003; 60(2): 196 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bekelman, Y. Li, and C. P. Gross Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review JAMA, January 22, 2003; 289(4): 454 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A.G.M. De Smet Herbal Remedies N. Engl. J. Med., December 19, 2002; 347(25): 2046 - 2056. [Full Text] [PDF]
|
|
|
|
|
|
Z. Di Blasi, T. J Kaptchuk, J. Weinman, and J. Kleijnen Informing participants of allocation to placebo at trial closure: postal survey BMJ, December 7, 2002; 325(7376): 1329 - 1329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Graham, A. K. Wutoh, R. D. Wutoh, J. P. Hampson, J. N. Harvey, S. A. Goldman, P. J. Greene, T. J. La Vaque, K. E. Lasser, S. J. Woolhandler, et al. Postmarketing Surveillance and Black Box Warnings JAMA, August 28, 2002; 288(8): 955 - 959. [Full Text] [PDF]
|
|
|
|
|
|
F. G. Miller and A. F. Shorr Unnecessary Use of Placebo Controls: The Case of Asthma Clinical Trials Arch Intern Med, August 12, 2002; 162(15): 1673 - 1677. [Full Text] [PDF]
|
|
|
|
|
|
W. Jonas, D. Wheatley, G. I. Spielmans, A. Volp, K. Linde, D. Melchart, C. D. Mulrow, M. Berner, J. Cott, K. L. Wisner, et al. St John's Wort and Depression JAMA, July 24, 2002; 288(4): 446 - 449. [Full Text] [PDF]
|
|
|
Article
